Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: A prospective study in 60 patients in Tunisia

Abstract

GEMCITABINE in monotherapy because of performance status (2-3) and/or unfitness to cisplatin, while 13% received gemcitabine combined with oxaliplatin(GEMOX). The objective response rate was 16%. After a median follow-up of 08 months: Overall survival was 7 months and progression-free survival was 2.5 months. Conclusion: Biliary tract cancers have a non-negligible incidence by being the fifth of digestive cancer. The poor prognosis of our patients is mainly related to the juxta-hepatic and para-pedicular situation of tumors and the difficulties of an early diagnosis. Conventional chemotherapy is still the mainstay treatment in the lack of new targeted therapies. Therefore, further research is needed to improve the outcome of patients.